Skip to main content

Table 2 Treatment regimena

From: Albumin treatment regimen for type 1 hepatorenal syndrome: a dose–response meta-analysis

Study Patients Albumin dose (g) Vasoconstrictor Treatment duration (d)
Randomized    Type Dose (mg)  
Alessandria et al., 2007 [18] 5 350 terlipressin 55 7.6
  4 406 noradrenaline 188 7.2
Martín-Llahí et al., 2008 [19] 17 190 terlipressin 66 7.0
Neri et al., 2008 [20] 26 836 terlipressin 36 19.0
Sanyal et al., 2008 [21] 56 304 terlipressin 28 6.3
Sharma et al., 2008 [22] 20 243 terlipressin 47 8.1
  20 234 noradrenaline 187 7.8
Silawat et al., 2011 [27] 30 88 terlipressin 10 7.0
Singh et al., 2012 [29] 23 156 terlipressin 24 7.8
  23 186 noradrenaline 132 9.3
Tavakkoli et al., 2012 [30] 9 720 midodrine/octreotide 270/5.4 18.0
  6 720 noradrenaline 146 18.0
Prospective      
Angeli et al., 1999 [13] 5 300 midodrine/octreotide 630/9.6 20.0
Uriz et al., 2000 [14] 6 358 terlipressin 48 10.6
Mulkay et al., 2001 [15] 12 200 terlipressin 72 26.0
Wong et al., 2004 [17] 14 700 midodrine/octreotide 35/8.4 14.0
Muñoz et al., 2009 [23] 13 592 terlipressin 41 9.6
Rivero et al., 2010 [26] 41 250 terlipressin 63 7.0
Salerno et al., 2011 [1] 40 235 terlipressin 63 8.7
  24 235 midodrine/octreotide 207/2.8 8.7
Narahara et al., 2012 [28] 8 162 terlipressin 18 6.3
Moreau et al., 2002 [16] 99 433 terlipressin 36 11.4
Skagen et al., 2009 [24] 49 368 midodrine/octreotide 222/3.6 8.4
von Kalckreuth et al., 2009 [25] 24 193 terlipressin 27 7.1
  1. aIndicated doses are mean cumulative values.